Maintaining Buy Rating on Y-Mabs Therapeutics: A Financial and Clinical Catalyst Outlook

Y-Mabs Therapeutics (YMAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock and has a $22.00 price target.

Robert Burns has given his Buy rating due to a combination of factors surrounding Y-Mabs Therapeutics’ financial outlook and upcoming clinical catalysts. Despite a recent top- and bottom-line miss, where Y-Mabs reported a slightly higher net loss per share and lower sales for DANYELZA than anticipated, the company’s financial guidance for the year ahead remains robust. Burns is encouraged by the company’s reiterated revenue projections for DANYELZA and controlled operating expenses. Significantly, Y-Mabs has a cash reserve sufficient to fund operations into 2027, which underscores a stable financial position.
Moreover, Burns’s optimism is fueled by several upcoming events that could potentially enhance Y-Mabs’ valuation. These include a variety of clinical trials and data readouts scheduled for the near future, which if successful, may lead to increased adoption and approval of the company’s therapies. Burns employs a discounted cash flow (DCF) approach to valuation, factoring in probabilities of approval for various treatments. Despite the inherent risks associated with drug development and market penetration, the report’s raised price target reflects confidence in the company’s pipeline and strategic execution.

In another report released on May 7, Canaccord Genuity also maintained a Buy rating on the stock with a $26.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Y-Mabs Therapeutics (YMAB) Company Description:

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.